Newsletter July 2017

Awareness: The PCCN-Toronto and Side by Side Prostate Cancer Support Groups Newsletter. In this Issue: Another fabulous  “Do it for dads” Walk Run! – complete with photos May Awareness Night: Dr. Jeff Appelmann: Naturopathic Approaches to Prostate Cancer and Prostate Health – Vidoe coming soon Volunteer Dinner at the Mandarin In Memoriam update July Awareness Night: Dr. Nathan Perils:  Focal Therapy Ask the Doctor: Dr. Gerard Morton – The Current Status of Brachytherapy Dick Arai 1928-2017 The 2017 awareness nights schedule Read it by clicking the link below to open the pdf file: July_2017_Newsletter

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. Read the article here.

New IsoPSA assay detects prostate cancer more precisely than current tests

A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease. Read the article here.


Immunotherapy is an exciting new field of study that is designed to boost the body’s immune system to fight cancer. It uses materials either made by the body or in a lab to improve, target or restore immune function. There are different types of immunotherapy including vaccines, monoclonal antibodies and non-specific immunotherapies. In prostate cancer, a treatment vaccine helps the body’s immune system fight cancer by training it to recognize and destroy cancer cells. Read the article here.

Active Surveillance in Men under 60

Younger age at diagnosis of low-risk prostate cancer was independently associated with decreased risk of disease progression in men managed with active surveillance, researchers reported. Read the article here. Active surveillance is a reasonable option for carefully selected men under 60 with low-risk prostate cancer. However, patients must be surveyed closely and understand the significant risk of ultimately needing treatment. Read the article here.

Scroll to Top